PIK-108 |
| Catalog No.GC62340 |
PIK-108 est un inhibiteur allostérique sélectif p110β/p110δ non compétitif pour l'ATP.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 901398-68-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PIK-108 is a non-ATP competitive, allosteric p110β/p110δ selective inhibitor[1].
PIK-108 (0.1-10 μM; 1 hour) blocks phosphorylation of PKB/Akt[1].
[1]. Zachary A Knight, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47.
[2]. Jack S Chen, et al. Characterization of structurally distinct, isoform-selective phosphoinositide 3’-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol Cancer Ther. 2008 Apr;7(4):841-50.
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *